Posters

Association between vitreoretinal interface status and the efficacy of intravitreous ranibizumab for macular edema secondary to branch retinal vein occlusion

Poster Details

First Author: Y.Miwa JAPAN

Co Author(s):    S. Ooto   T. Murakami   Y. Muraoka   Y. Iida   K. Suzuma   A. Tsujikawa              

Abstract Details



Purpose:

To investigate the association between vitreoretinal interface status and the efficacy of intravitreous ranibizumab (IVR) for macular edema (ME) secondary to branch retinal vein occlusion (BRVO) at 1 year.

Setting:

A non-randomized prospective interventional study was conducted.

Methods:

Forty-five eyes of 45 treatment-naive patients with ME secondary to BRVO (best-corrected visual acuity [BCVA] worse than 20/32; age, >50 years) who received IVR treatment at Kyoto University Hospital between September 2013 and September 2015 were included this study. All the patients received initial 3-monthly intravitreal injections of ranibizumab and were followed up every month. Further injections of ranibizumab were given when ME recurred with a concomitant decrease in visual acuity. Ophthalmic examination, including BCVA and optical coherence tomography (OCT), were performed at each visit. Central retinal thickness (CRT) was measured automatically by using built-in software. The presence of posterior vitreous detachment (PVD) and vitreomacular adhesion (VMA) was assessed by using vitreous-enhanced B scans.

Results:

The mean (SD) age of the patients was 71.4±7.9 years. At baseline, PVD was observed in 29 eyes (PVD+ group) but not in 16 eyes (PVD− group). In the PVD− group, VMA was observed in 4 eyes. No significant differences in mean age, BCVA, and CRT were found between the two groups (P=0.264, 0.15, and 0.773, respectively). At month 12, the mean LogMAR BCVA was improved significantly from that at baseline (from 0.357 to 0.063, P<0.001). No significant differences in mean BCVA, CRT, and number of injections were found between the two groups (P=0.805, 0.109, and 0.898, respectively). In the PVD− group, PVD was observed in 9 eyes (56.3%) within one year after the intimal injection. Eyes with PVD development had significantly lower CRT (P=0.047) and needed fewer additional injections than the eyes without PVD (1.3 vs. 2.9, P=0.061). In the PVD− group, the mean LogMAR BCVA was significantly better in the eyes with VMA than in those without VMA (−0.079 vs. 0.10, P=0.001).

Conclusions:

Although baseline vitreoretinal interface status did not affect 1-year visual prognosis, the eyes with PVD development needed fewer additional ranibizumab injections for ME secondary to BRVO. In the eyes without PVD, VMA was associated with better visual prognosis.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy